Numerous Swiss and European start-ups and SME’s applied for this year’s Swiss Innovation Challenge! In the 1st pitching round, 100 innovative participants presented their projects in front of a competent jury. Selected start-ups also benefit from a comprehensive support platform with individual coaching, tailored education, and mentoring, as well as get access to potential investors and business partners.
Next, 50 ventures move on to the 2nd pitching round in this challenge. Start-ups and SMEs continue to receive expert support to accelerate their innovative projects and face the competition through three elimination rounds in total. In addition to the main award, participants can win special prizes in the fields of “Globalization”, “Life Sciences” and “Construction”.
Within the Life Sciences Start-ups, we are proud to see 3 HEMEX portfolio start-ups!
GeneLook enables patients to actively use their genetic data in a meaningful way by allowing the healthcare ecosystem to utilize their data in order to facilitate discoveries of new treatments. GeneLook strategically focuses on rare disease patients, to further characterize their diseases, and to improve and accelerate the medical treatment journey.
Hi-D Imaging is an ETHZ spin-off aiming to revolutionize the cardiovascular sector by making personalized heart valve replacement therapy a reality. Hi-D (pronounced “Heidi”) develops the world’s first AI-based pre-operational planning platform to assess different heart valves for the patient-specific anatomy, and recommends the optimum shape and size of the valve to the surgeon. The start-up’s technology will increase the quality-of-life of the patient, decrease complications, reduce long-term costs, and increase the overall success rate of the surgery.
Resistell is an EPFL spin-off developing world’s fastest antibiotic susceptibility test in order to help physicians around the world save patients’ lives. Resistell’s solution is needed more than ever due to increasing antimicrobial resistance, emergency of side effects due to potent antibiotics, not the least in the context of global pandemics. Its life-saving technology is based on the detection of movement caused by living bacterial cells and provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered
HEMEX is a Bench-to-Market Life Science Provider. We support life science start-ups with a wide range of expertise, either in-house or via our network of pre-qualified experts, laboratories, CMOs, warehouses, logistic partners and affiliates. Our development team supports with Quality Assurance, Medical and Regulatory Affairs, Clinical Operations, Biostatistics, Medical Writing and eSubmissions.